Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin: Diagnostik und Therapie interdisziplinär dargestellt

W Hofmann; I Kötter; S Winterhalter; S Krupp

doi:10.1007/s00393-024-01484-0

Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin

Standard

Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin : Diagnostik und Therapie interdisziplinär dargestellt. / Hofmann, W; Kötter, I; Winterhalter, S; Krupp, S.

in: Z RHEUMATOL, Jahrgang 83, Nr. 2, 03.2024, S. 112-121.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Fortbildungsbeitrag › Lehre › Begutachtung

Harvard

Hofmann, W, Kötter, I, Winterhalter, S & Krupp, S 2024, 'Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin: Diagnostik und Therapie interdisziplinär dargestellt', Z RHEUMATOL, Jg. 83, Nr. 2, S. 112-121. https://doi.org/10.1007/s00393-024-01484-0

APA

Hofmann, W., Kötter, I., Winterhalter, S., & Krupp, S. (2024). Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin: Diagnostik und Therapie interdisziplinär dargestellt. Z RHEUMATOL, 83(2), 112-121. https://doi.org/10.1007/s00393-024-01484-0

Vancouver

Hofmann W, Kötter I, Winterhalter S, Krupp S. Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin: Diagnostik und Therapie interdisziplinär dargestellt. Z RHEUMATOL. 2024 Mär;83(2):112-121. https://doi.org/10.1007/s00393-024-01484-0

Bibtex

@article{36245abff281472b9f2431bd7ef9299a,

title = "Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin: Diagnostik und Therapie interdisziplin{\"a}r dargestellt",

abstract = "Polymyalgia rheumatica is the second most frequent inflammatory rheumatic disease in people aged over 50 years, after rheumatoid arthritis. It is characterized by pain and morning stiffness in the region of the shoulders, hip girdle and neck. It can be associated with giant cell arteritis (CGA). Treatment with glucocorticoids is indispensable. The duration of treatment varies and often exceeds 1 year. The additive administration of methotrexate is an option for saving glucocorticoids. The biologicals tocilizumab or secukinumab are very promising alternatives. The course of treatment should be closely monitored for inflammation parameters, glucocorticoid side effects, pain, visual acuity, depression, activities of daily living and especially related to functions of the upper extremities. The geriatric assessment plays an important role in the management of this condition.",

author = "W Hofmann and I K{\"o}tter and S Winterhalter and S Krupp",

note = "{\textcopyright} 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2024",

month = mar,

doi = "10.1007/s00393-024-01484-0",

language = "Deutsch",

volume = "83",

pages = "112--121",

journal = "Z RHEUMATOL",

issn = "0340-1855",

publisher = "D. Steinkopff-Verlag",

number = "2",

}

RIS

TY - JOUR

T1 - Polymyalgia rheumatica – eine Herausforderung in der Altersmedizin

T2 - Diagnostik und Therapie interdisziplinär dargestellt

AU - Hofmann, W

AU - Kötter, I

AU - Winterhalter, S

AU - Krupp, S

PY - 2024/3

Y1 - 2024/3

N2 - Polymyalgia rheumatica is the second most frequent inflammatory rheumatic disease in people aged over 50 years, after rheumatoid arthritis. It is characterized by pain and morning stiffness in the region of the shoulders, hip girdle and neck. It can be associated with giant cell arteritis (CGA). Treatment with glucocorticoids is indispensable. The duration of treatment varies and often exceeds 1 year. The additive administration of methotrexate is an option for saving glucocorticoids. The biologicals tocilizumab or secukinumab are very promising alternatives. The course of treatment should be closely monitored for inflammation parameters, glucocorticoid side effects, pain, visual acuity, depression, activities of daily living and especially related to functions of the upper extremities. The geriatric assessment plays an important role in the management of this condition.

AB - Polymyalgia rheumatica is the second most frequent inflammatory rheumatic disease in people aged over 50 years, after rheumatoid arthritis. It is characterized by pain and morning stiffness in the region of the shoulders, hip girdle and neck. It can be associated with giant cell arteritis (CGA). Treatment with glucocorticoids is indispensable. The duration of treatment varies and often exceeds 1 year. The additive administration of methotrexate is an option for saving glucocorticoids. The biologicals tocilizumab or secukinumab are very promising alternatives. The course of treatment should be closely monitored for inflammation parameters, glucocorticoid side effects, pain, visual acuity, depression, activities of daily living and especially related to functions of the upper extremities. The geriatric assessment plays an important role in the management of this condition.

U2 - 10.1007/s00393-024-01484-0

DO - 10.1007/s00393-024-01484-0

M3 - Fortbildungsbeitrag

C2 - 38285216

VL - 83

SP - 112

EP - 121

JO - Z RHEUMATOL

JF - Z RHEUMATOL

SN - 0340-1855

IS - 2

ER -